The following video interviews with kidney cancer experts from the USA and Europe were conducted at the recent European Society of Medical Oncology (ESMO) 2018 congress in Munich last month. The interviews cover topics such as a new treatment for VHL-associated kidney cancer, real world effectiveness of pazopanib for renal cell carcinoma (RCC), recommendations for choosing TKIs or immunotherapy for metastatic RCC, and insights from the ATLAS trial on the use of TKIs for adjuvant therapy. The videos were produced by Practice Update and UroToday.

ESMO 2018: PT2977 for VHL-Associated Renal Cell Carcinoma

ESMO 2018: Real World Effectiveness of Pazopanib in Patients With Intermediate Risk Renal Cell Carcinoma

ESMO 2018: Clinical Recommendations for Choosing TKIs or Immunotherapy for mRCC

ESMO 2018: Contextualized Insights From ATLAS on the Use of TKIs in Adjuvant mRCC Treatment

ESMO 2018: Update on Immunotherapy Advances in Renal and Bladder Cancer – Cora Sternberg